Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- TECD -18.9%, AMBA -13.1%, COO -1.9%
Other news:
- MGNX -8.5% (MacroGenics announces termination of duvortuxizumab collaboration and license agreement with Janssen)
- PGNX -1.9% (Progenics Pharm announces study results that show treatment with AZEDRA produced clinically meaningful and durable responses across multiple study endpoints, including radiographic tumor response, tumor biomarker response, and overall survival), .
Analyst comments:
- N/A.